细胞学不确定甲状腺结节的分子检测更新
约15%至30%的甲状腺细针穿刺(FNA)标本细胞学结果不确定,给患者和临床医生带来管理挑战。本文综述了目前市场上用于细胞学不确定甲状腺FNA标本的4种分子检测(Afirma、ThyroSeq、ThyGenX/ThyraMIR和RosettaGX Reveal)的方法学、临床验证及近期同行评议文献,指出这些检测可改善风险分层,但需结合验证数据及上市后表现文献进行选择和解读。
要点
- 约15%至30%的甲状腺FNA标本细胞学结果不确定。
- 四种商业分子检测可用于不确定甲状腺FNA的风险分层。
- 需结合验证研究和上市后文献解读检测结果。
核心结论
- 四种商业分子检测为甲状腺细胞学不确定结节提供了独特方法来改善风险分层。
- 熟悉验证研究数据及上市后表现的新兴文献有助于临床有意义地选择和解读这些检测。
研究设计与样本
- 综述,检索PubMed同行评议文献、公司网站和代表提供的数据以及作者个人经验。
主要发现
- 约15%至30%的甲状腺细针穿刺标本细胞学分类为不确定。
- Afirma、ThyroSeq、ThyGenX/ThyraMIR和RosettaGX Reveal是当前市场上用于细胞学不确定甲状腺FNA标本的四种分子检测。
临床怎么用
- 临床医生可依据验证研究数据和上市后文献选择并解读分子检测,以改善不确定甲状腺结节的风险分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: - Approximately 15% to 30% of thyroid nodules that undergo fine-needle aspiration are classified as cytologically indeterminate, presenting management challenges for patients and clinicians alike. During the past several years, several molecular tests have been developed to reduce the diagnostic uncertainty of indeterminate thyroid fine-needle aspirations. OBJECTIVE: - To review the methodology, clinical validation, and recent peer-reviewed literature for 4 molecular tests that are currently marketed for cytologically indeterminate thyroid fine-needle aspiration specimens: Afirma, ThyroSeq, ThyGenX/ThyraMIR, and RosettaGX Reveal. DATA SOURCES: - Peer-reviewed literature retrieved from PubMed search, data provided by company websites and representatives, and authors' personal experiences. CONCLUSIONS: - The 4 commercially available molecular tests for thyroid cytology offer unique approaches to improve the risk stratification of thyroid nodules. Familiarity with data from the validation studies as well as the emerging literature about test performance in the postvalidation setting can help users to select and interpret these tests in a clinically meaningful way.
引用
- Nishino M, Nikiforova M. Update on Molecular Testing for Cytologically Indeterminate Thyroid Nodules. Arch Pathol Lab Med. 2018. PMID: 29336606. doi:10.5858/arpa.2017-0174-RA
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。